{
  "source": "PA-Notification-Ibrance.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1154-13\nProgram Prior Authorization/Notification\nMedication Ibrance® (palbociclib)\nP&T Approval Date 4/2015, 4/2016, 3/2017, 5/2017, 5/2018, 5/2019, 5/2020, 5/2021,\n5/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nIbrance® (palbociclib) is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-\npositive human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic\nbreast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy, or in\ncombination with Faslodex® (fulvestrant) in patients with disease progression following\nendocrine therapy.\nThe use of an aromatase inhibitor in men with breast cancer is ineffective without concomitant\nsuppression of testicular steroidogenesis. The National Comprehensive Cancer Network (NCCN)\nrecommends the use of Ibrance as single-agent therapy for unresectable retroperitoneal well-\ndifferentiated/dedifferentiated liposarcoma (WD-DDLS).\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Ibrance will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Breast Cancer\n1. Initial Authorization\na. Ibrance will be approved based on all of the following criteria:\n(1) Diagnosis of advanced, recurrent, or metastatic breast cancer\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Disease is hormone-receptor (HR)-positiv",
    "ed based on all of the following criteria:\n(1) Diagnosis of advanced, recurrent, or metastatic breast cancer\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Disease is hormone-receptor (HR)-positive\n-AND-\n(3) Disease is human epidermal growth factor receptor 2 (HER2)-negative\n-AND-\n(4) One of the following:\n(a) Used in combination with an aromatase inhibitor (e.g., anastrozole,\nletrozole, exemestane)\n-OR-\n(b) Used in combination with Faslodex (fulvestrant)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ibrance will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Ibrance therapy\nAuthorization will be issued for 12 months.\nC. Well-Differentiated/Dedifferentiated Liposarcoma (WD-DDLS)\n1. Initial Authorization\na. Ibrance will be approved based on the following criterion:\n(1) Diagnosis of unresectable retroperitoneal WD-DDLS\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ibrance will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Ibrance therapy\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n2\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or ",
    "tial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Ibrance capsules [package insert]. New York, NY: Pfizer Labs; September 2023.\n2. Ibrance tablets [package insert]. New York, NY: Pfizer Labs; September 2023.\n3. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed\nDecember 26, 2024.\nProgram Prior Authorization/Notification – Ibrance (palbociclib)\nChange Control\n4/2015 New program.\n4/2016 Annual review. Updated background and criteria to include new\nindication for combination use with fulvestrant and NCCN\nrecommended use as a single agent for WD-DDLS.\n1/2017 Administrative change to correct spacing.\n3/2017 Annual review. Change Member to Patient in Coverage Criterion.\nUpdated formatting.\n5/2017 Updated background and criteria to include new indication for\ncombination use with an aromatase inhibitor as opposed to letrozole\nalone. Updated formatting and reference.\n5/2018 Annual review. Updated background information without change to\nclinical intent. Updated references.\n5/2019 Annual review. Updated coverage criteria to allow for in recurrent\nbreast cancer, added requirement of unresectable WD-DDLS, and\nremoved disease progression following endocrine therapy criteria per\nNCCN recommendations. Updated background and references.\n5/2020 Annual review. Updated coverage criteria for WD-DDLS per NCCN\n© 2025 UnitedHealthcare Services, Inc.\n3\nrecommendations. Updated background and references.\n5/2021 Annual review. No changes to coverage criteria. Updated references.\n5/2022 Annual review. No changed to coverage criteria. Updated references.\n2/2023 Updated background to include pre-/perimenopausal women per FDA\nlabel. Added stated mandate and updated references.\n2",
    "\n5/2022 Annual review. No changed to coverage criteria. Updated references.\n2/2023 Updated background to include pre-/perimenopausal women per FDA\nlabel. Added stated mandate and updated references.\n2/2024 Annual review. Specified type of unresectable WD-DDLS to be\nretroperitoneal per NCCN recommendation. Updated references to\nseparate out package insert references for Ibrance capsules and tablets.\n2/2025 Annual review. No changes to clinical criteria.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}